Ocular assessment of patients treated with tamoxifen.

M. Beck, Mills Pv

PubMed · 1980 · 43 citations · 0 references

Concepts

Abstract

Tamoxifen is a specific estrogen antagonist used in the treatment of breast cancer. In a previous study, corneal and retinal changes were reported in four patients receiving high-dose tamoxifen therapy for greater than 1 year. Nineteen patients treated with tamoxifen for periods of 3 months to 4 years at normal dose levels have been studied and no ocular changes attributable to the drug were observed.